Close menu




February 3rd, 2021 | 08:10 CET

Nokia, Blackrock Gold, Delivery Hero: Where profits are sustainable

  • Investments
Photo credits: pixabay.com

The world is changing. For many people, this brings with its drastic changes. On the stock market, change offers great opportunities: For every trend, there are also suitable companies that profit from the Covid era's changes. Some of these trends are sustainable, and others are only good for a quick fix. We do the checks: Three trend stocks and their sustainability.

time to read: 3 minutes | Author: Nico Popp
ISIN: CA09258M1014 , FI0009000681 , DE000A2E4K43

Table of contents:


    Nokia: What is left of the Reddit hype?

    A few weeks ago, the Nokia share was a rather dull stock - until Reddit gamblers drove the value up. The high-flyer stock of the 1990s has a turbulent history and even faced bankruptcy at one point years ago. But Nokia has reinvented itself and now operates as a network supplier. Today, mobile data networks are just as important as highways or power lines. Although the Finns' products are more expensive than the Chinese competition, there are reservations about Huawei. If Chinese companies were to equip our data networks, some observers say it would be a security risk.

    Investment strategists, such as Kim Catechis of the US investment boutique Martin Currie, pointed out years ago that these security concerns could lead to a situation where standard market mechanisms around 5G infrastructure are undermined and Nokia, as a European equipment supplier, can compete despite higher costs. Meanwhile, many regions have turned down 5G hardware from China.

    For Nokia, these are favorable conditions. Moreover, since the stock had been targeted by Reddit traders and went on a roller coaster ride at the end of January, it no longer seems uninteresting. Investors need to be careful when they get in, though. As a network equipment supplier, Nokia tends to be a conservative stock that can play to its strengths over the long term. However, since the 5G pie has already been widely distributed, investors should not expect any big surprises.

    Blackrock Gold: With fresh capital and silver fantasy

    Blackrock Gold's stock, on the other hand, is always good for surprises. The Company operates two projects in Nevada around gold and silver. Blackrock's priority is the Tonopah West project. The Company has already drilled 24,000 meters here in 2020 and extended the target zone "Victor" by 500 meters at the end of December due to positive results. Further results from the drilling program are pending in the coming weeks.

    Blackrock Gold already believes that Tonopah-West offers further exploration potential, which will be explored in additional measures in 2021. The Company most recently announced a CAD 9 million financing at CAD 0.72 per share to fund these drilling projects. Following the financing, Blackrock's share price rallied significantly but is still nearly 50% below last summer's level.

    In general, Blackrock's share price has formed a solid base over the past months and has repeatedly shown signs of dynamic breakouts. The fact that there is fantasy in the value is also proven by the considerations to spin off the Silver Cloud silver project. Blackrock started a drill program here at over 3,500 meters to show similarities to Hecla Mining's nearby Hollister mine. Given the strong performance of the flagship Tonopah-West project and Silver Cloud's silver fantasy, the stock appears to be worth a look at current levels.

    Delivery Hero: Is the restaurant industry threatening a comeback?

    Similar to Blackrock Gold, Delivery Hero's stock also twitched suspiciously higher at one point in recent days. The fantasy behind Delivery Hero is simple: More and more people are working at home, which creates an additional market for meal delivery. The stock has consolidated over the past few weeks. On a one-year horizon, the stock has a yield of around 80% - so the long-term upward trend is intact.

    Although Delivery Hero will continue to defend market share in the future, it is to be expected that people will again increasingly seek out restaurants as the end of the pandemic approaches. Looking ahead to the next few quarters, this development could put a damper or two on things. However, the business model appears promising in the long term, although Delivery Hero is not immune to competition. After the rise of the past year, investors should be cautious with Delivery Hero. Although share price gains are possible again, the quarterly figures must keep pace with the valuation.

    The situation is similar for Nokia. Short-term gains resulting from short squeezes are unlikely to be sustainable, although the stock has more substance than Delivery Hero. In contrast, Blackrock Gold's situation is entirely open: If gold and silver have to stay in the ground due to weak framework data, there is nothing for shareholders to gain. However, if the past months' positive expectations for the projects of Blackrock Gold are confirmed, high profits could await investors.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read